B iopharmaceutical and medical device companies rely on investigative sites to complete their clinical trials. Building strong relationships with high-qual- ity sites is critical to addressing a number of key challenges, from the growing number of trials to mounting pressures that minimize cycle times. Y et investigative sites consistently express their dissatisfaction with the grant payment process and highlight this as one of their biggest pain points in participating in clinical trials — potentially keeping new sites from entering the industry and tempting existing sites to drop out of clinical trials due to slow payments. Many sponsors and CROs continue to use standalone spread- sheets and databases to manage grant calculations, increas- ing financial risk and the probability of error

Join for free to read